Sanara MedTech Inc. (SMTI)
NASDAQ (CM) NASDAQ (CM) Primary 
Sanara MedTech: From Cash Burner To Profitable Growth
Sanara MedTech delivered a strong Q1 2026, with 19% revenue growth, 93%+ gross margins, and its first GAAP profit in years. SMTI's strategic discontinuation of the THP segment has materially improved profitability, allowing management to focus on the high-return Surgical business. Operating margins now exceed 10%, and guidance for 2026 revenue is $116M–$121M, supporting a Buy rating despite the recent 30% stock rally.
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) Q4 Earnings Miss Estimates
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago.
Sanara MedTech (SMTI) Upgraded to Strong Buy: Here's What You Should Know
Sanara MedTech (SMTI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sanara MedTech Inc. (SMTI) Tops Q3 Earnings Estimates
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.34 per share a year ago.
Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript
Sanara MedTech Inc. ( SMTI ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Seth Yon - President, CEO & Director Elizabeth Taylor - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Daniel Journey Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Sanara MedTech Third Quarter of 2025 Earnings Conference Call.
Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Elizabeth B. Taylor - Chief Financial Officer Ronald T.
Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates
Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.41 per share a year ago.
Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb
Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.
Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates
Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago.
Sanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar?
Sanara MedTech (SMTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
